→ Menlo Park, CA-based Grail has banked more than $900 million in its first close of a big Series B led by Arch Venture Partners. J&J Innovation made a big contribution, drawn by the upstarts plans to revolutionize the early detection and treatment of cancer. “We envision a global community that benefits from early-stage cancer detection where fewer individuals face the anguish of late-stage diagnosis and devastating outcomes,” said Jeff Huber, Grail’s CEO. “I believe that Grail’s approach leveraging high-intensity sequencing, population-scale clinical studies, and state of the art Computer Science and Data Science is unparalleled in the field of cancer detection. Our team made tremendous progress in 2016 and I look forward to additional clinical and strategic milestones.”
→ Cambridge, MA-based Alnylam says the EMA has added its RNAi drug givosiran (ALN-AS1), targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias, to its PRIME project for early access. PRIME may put this drug on an accelerated pathway to an early approval.
→ Veloxis Pharmaceuticals says it will close its office in Edison, NJ and concentrate its staff in North Carolina.
Get Endpoints News in your inbox
News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.
You're subscribing to Endpoints News
John Carroll, Editor and Co-Founder
We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.